Eczema affects 10% of adults, with higher prevalence in women. Rosacea affects an estimated 16 million Americans, predominantly women. Psoriasis affects men and women roughly equally, but hormonal fluctuations during menstruation, pregnancy, and menopause can trigger flares in women.
These conditions share common biological themes: immune dysregulation, chronic inflammation, and skin barrier dysfunction. Several peptides target these same pathways. Understanding which peptide addresses which mechanism helps evaluate whether — and how — peptide therapy might fit alongside conventional dermatological care.
Eczema (atopic dermatitis)
Eczema involves a defective skin barrier (often related to filaggrin gene mutations), Th2-dominant immune dysregulation, and chronic inflammation. The barrier lets in allergens and irritants; the immune system overreacts; inflammation perpetuates the cycle.
GHK-Cu is the most mechanistically relevant peptide for eczema. Its role in collagen synthesis and extracellular matrix remodeling supports barrier repair. Its anti-inflammatory properties (downregulation of IL-6 and TNF-α) address the inflammatory component. Topical GHK-Cu applied to intact (non-weeping, non-broken) eczematous skin is the delivery method some clinicians explore — never on active, open lesions.
KPV inhibits NF-κB, the transcription factor that drives inflammatory cytokine production in eczema. Preclinical data shows KPV reduces inflammation in models of inflammatory skin disease. Its relevance to eczema is through immune modulation rather than barrier repair — a different axis than GHK-Cu.
Rosacea
Rosacea involves vascular dysregulation (flushing, visible blood vessels), immune-mediated inflammation, and — in many cases — overgrowth of Demodex mites on the skin. The innate immune system's response to Demodex involves cathelicidins, the peptide family that includes LL-37.
LL-37 has a complex relationship with rosacea. Paradoxically, elevated LL-37 levels have been found in rosacea-affected skin, and abnormal processing of the LL-37 precursor (hCAP18) may contribute to rosacea inflammation rather than resolve it. This means exogenous LL-37 for rosacea is not straightforward — it's not simply a case of "more LL-37 = better." The research is nuanced and the clinical implications are unresolved.
GHK-Cu may be relevant to rosacea through its anti-inflammatory and tissue-remodeling properties, but evidence specific to rosacea is sparse. Some clinicians use topical GHK-Cu for rosacea patients, but results are anecdotal.
Psoriasis
Psoriasis is a Th17-driven autoimmune condition where the immune system attacks skin cells, causing rapid cell turnover, thickened plaques, and chronic inflammation. The NF-κB pathway is central to psoriasis pathology.
KPV is the most mechanistically relevant peptide for psoriasis. Its inhibition of NF-κB directly targets the inflammatory cascade driving plaque formation. Preclinical data in models of inflammatory skin disease supports this mechanism. Clinical data in psoriasis patients is not yet available.
BPC-157 has anti-inflammatory and tissue-repair properties that may be relevant to psoriasis, but its primary research focus has been gut and musculoskeletal tissue, not skin. The connection between gut health (which BPC-157 targets) and psoriasis severity (which correlates with gut inflammation in some patients) provides an indirect rationale for BPC-157 in psoriasis — through the gut-skin axis rather than direct skin application.
How to think about peptides for skin conditions
Start with your dermatologist's treatment plan. If you're considering adding peptides, bring the conversation to your dermatologist — not the other way around. A provider who understands your specific condition, its severity, and your current treatment can assess whether a peptide adjunct makes sense and how to monitor for interactions.
Topical peptides (GHK-Cu serums, for example) carry lower risk than systemic peptides and can be explored with fewer safety concerns. Injectable peptides for skin conditions represent a higher commitment and should be medically supervised.
Set realistic expectations. A peptide is not going to clear a moderate-to-severe psoriasis flare. It might, alongside appropriate treatment, contribute to faster resolution, reduced inflammation between flares, or improved barrier function over time. The operative words are "might" and "alongside." Not "will" and "instead of."